スタチンが筋肉を傷つける仕組みとその防止法を解明(UBC researchers uncover how statins harm muscles―and how to stop it)

ad

2025-11-26 カナダ・ブリティッシュコロンビア大学(UBC)

University of British Columbia(UBC)の研究チームは、コレステロール低下薬 Atorvastatin をはじめとするスタチンが筋肉障害を引き起こすメカニズムを、原子レベルで初めて明らかにした。彼らはクライオ電子顕微鏡を用いて、スタチンが筋細胞内のカルシウムチャネル RyR1 に結合し、チャネルを不正に開かせてカルシウムの異常漏出を誘発する構造を可視化。このカルシウム漏れが筋細胞に毒性を与え、筋痛や筋力低下、まれには重篤な筋障害を引き起こす原因であると示された。今回の結果は、世界中で広く使われてきたスタチンの副作用に関する長年の疑問に対する構造生物学的な解明を提供するものであり、心血管疾患治療の安全性向上につながる可能性がある。

スタチンが筋肉を傷つける仕組みとその防止法を解明(UBC researchers uncover how statins harm muscles―and how to stop it)This illustration, based on what researchers were able to observe using high-resolution macromolecular cryo-electron microscopy, shows statin moelcules in black binding to the RyR1 protein. (Source: The Bioelectricity Lab, UBC Life Sciences Institute)

<関連情報>

クライオ電子顕微鏡により、スタチントリプレットによるリアノジン受容体への連続的な結合と活性化が明らかになった Cryo-electron microscopy reveals sequential binding and activation of Ryanodine Receptors by statin triplets

Steven Molinarolo,Carmen R. Valdivia,Héctor H. Valdivia & Filip Van Petegem
Nature Communications  Published:20 November 2025
DOI:https://doi.org/10.1038/s41467-025-66522-0

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

Abstract

Statins are the most prescribed class of drugs and inhibit a key enzyme in the cholesterol biosynthesis pathway. Many patients have reported mild to severe muscle related symptoms and a subset are at risk for rhabdomyolysis. Sequence variants in RyR1, the skeletal muscle Ryanodine Receptor, correlate with intolerance to statins, but whether RyR1 can bind statins directly has remained unclear. Here we report cryo-EM structures of RyR1 in the absence and presence of atorvastatin, firmly establishing RyR1 as an unintended off-target. Our results show an unusual binding mode whereby three atorvastatin molecules bind together in a cleft formed by the pseudo-voltage sensing domain, making extensive interactions with each other and with RyR1. Atorvastatin activates RyR1 in a sequential way, whereby one statin per subunit can bind to the transmembrane region of a closed RyR1, with small structural perturbations that prime the channel for opening. Binding of two additional statins per subunit is associated with a widening of the pseudo-voltage sensing domain that triggers opening of the pore. Comparison with atorvastatin binding to HMG-CoA reductase, its intended target, offers clues on how to modify the statin to reduce RyR1 binding, while leaving binding to HMG-CoA reductase unperturbed.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました